Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosalt Regulatory News (SALT)

Share Price Information for Microsalt (SALT)

Share Price is delayed by 15 minutes
Get Live Data
35.50    0.00 (0.00%)
Bid:
32.00
Ask:
39.00
Spread: 7.00 (21.875%)
Market Cap: £20.49m
SALT Live PriceLast checked at - London Stock Exchange

Intraday Microsalt Share Chart

Signed Joint Development Agreement

27 Jan 2026 07:25

RNS Number : 5171Q
MicroSalt PLC
27 January 2026
 

27 January 2026

MicroSalt Plc

 

("MicroSalt" or the "Company")

 

Signed Joint Development Agreement

 

MicroSalt (AIM: SALT), a leading manufacturer of full-flavour natural salt with approximately 50% less sodium, is pleased to announce that it has entered into a formal Joint Development Agreement ("JDA") with Customer 3, one of the world's largest food, soft drink and snack manufacturers (the "Partner").

 

This agreement follows the Company's announcement on 14 November 2025 regarding the signing of a non-binding term sheet between the parties.

 

The JDA provides a framework for a four-year collaboration between MicroSalt and the Partner focused on the joint development of new food solutions that significantly reduce sodium content, while maintaining a salty and savoury taste experiences for consumers. The agreement reflects the continued expansion in both the depth and breadth of the relationship between the two parties and will continue to build on existing commercial engagements.

 

Unless otherwise expressly agreed within the scope of individual projects, no compensation will be exchanged between the parties, and each party will bear its own costs incurred in connection with the collaboration.

 

The signing of the JDA represents an important milestone for MicroSalt, providing increased visibility over future development activity and reinforcing the Company's position as a strategic partner to global food manufacturers seeking practical, scalable sodium-reduction solutions.

 

Rick Guiney, Chief Executive Officer of MicroSalt, commented:

"This further agreement with Customer 3 is a validation of MicroSalt's unique offering to the global food and beverage industry. Collaborating with one of the world's largest food, soft drink and snack manufacturers underlines the strength and versatility of our technology that addresses one of the food industry's most pressing challenges. We look forward to working evermore closely with Customer 3 to deliver healthier food products to consumers worldwide in the coming years."

 

 

Enquiries:

 

MicroSalt plc

info@microsaltinc.com

Rick Guiney (CEO)

Zeus (Nominated Adviser and Broker)

+44 (0)20 3829 5000

David Foreman / James Edis (Investment Banking)

Dom King (Broking) / Rupert Woolfenden (Sales)

Gracechurch Group (Financial PR)

+44 (0)20 4582 3500

Heather Armstrong, Alexis Gore, Rebecca Scott

 

 

About MicroSalt

 

MicroSalt® is disrupting the global salt market with its patented, full-flavour, low-sodium salt designed for both food manufacturers and consumers. Using proprietary micron-sized particles, MicroSalt® delivers the same salty taste as traditional salt with approximately 50% less sodium, offering a scalable solution to one of the world's most pressing health challenges. Year to date through 2025, MicroSalt® has contributed to more than 634M servings made healthier.

 

Excess sodium consumption is a leading contributor to cardiovascular disease, the world's number one cause of death. The World Health Organisation has targeted a 30% reduction in global sodium intake by 2025, a shift projected to save seven million lives by 2030. The economic case is equally compelling: in the UK alone, cardiovascular disease costs £19 billion annually, and reducing average daily salt intake by just one gram could save over 4,000 lives and £288 million each year. 

 

Operational since 2018, MicroSalt® has established a defensible IP portfolio, holding a granted US patent and 14 pending applications worldwide. These protections create significant barriers to entry in a market expected to grow exponentially as regulation and consumer demand accelerate.

 

MicroSalt® is ideally positioned for scale and market leadership, with clear pathways into food manufacturing, consumer channels, and ultimately the broader £10+ billion global salt market. MicroSalt® is more than a healthier alternative-it is a disruptive, category-defining solution poised to deliver significant commercial and societal impact.

 

For more information, please visit www.microsaltinc.co or follow on X @microSaltPLC.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
JVEMZGZMNNLGVZG
12
Date   Source Headline
5th Jun 20267:00 amRNSNotice of AGM
28th May 20267:07 amRNSFinal Results
28th Apr 20267:00 amRNS-RMicroSalt Launches MicroSalt Fibre
5th Mar 20267:00 amRNS-RNew UK customer
2nd Mar 20267:00 amRNS-RMicroSalt Reaches One Billion Servings Milestone
13th Feb 20267:00 amRNSGrant of options and PDMR dealings
27th Jan 20267:25 amRNSSigned Joint Development Agreement
12th Jan 20267:00 amRNSTrading Update
15th Dec 20252:17 pmRNSAdmission, Director Dealings and TVR
12th Dec 20252:30 pmRNSResult of Retail Offer
9th Dec 20254:35 pmRNSLaunch of Retail Offer
9th Dec 20252:40 pmRNSSubscription to raise £1.5 million
21st Nov 20253:38 pmRNSExercise of Stock Options and Total Voting Rights
14th Nov 20257:00 amRNSTrading Update
12th Nov 20257:00 amRNSNew Strategic Relationship with Daiya Foods
30th Sep 20257:00 amRNSUnaudited Half-yearly Report
1st Sep 20257:00 amRNSBoard changes
18th Aug 20257:00 amRNSH1 2025 Trading Update
11th Aug 20257:00 amRNSMissed related party transaction
6th Aug 20257:38 amRNSRelated Party Transaction
27th Jun 20253:48 pmRNSResult of AGM
6th Jun 202512:30 pmRNSHolding(s) in Company
2nd Jun 20257:01 amRNSNotice of Investor Presentation 9th June 2025
2nd Jun 20257:00 amRNSFinal Results Year Ended 31 December Notice of AGM
24th Apr 20257:00 amRNSQ1 2025 Business Update
24th Mar 20257:00 amRNS-RIFE London Innovation in Nutritious Foods
19th Mar 20257:00 amRNS-RFast Award 2025
25th Feb 20257:00 amRNS-RTechnology of the Year 2025 Award
14th Feb 20251:22 pmRNSNotification of Major Holdings
14th Feb 20251:06 pmRNSNotification of Major Holdings
7th Feb 20257:00 amRNSFurther Re Fundraising
5th Feb 20257:00 amRNSExercise of Stock Options and Total Voting Rights
3rd Feb 20257:00 amRNSOversubscribed Fundraising of £2.3Million
16th Jan 20257:00 amRNS-RFDA Nutrition information on packaged foods
6th Jan 20254:51 pmRNSResults of General Meeting
10th Dec 20247:00 amRNSShareholder Circular and Notice of General Meeting
30th Oct 20247:00 amRNSNew and Follow-on B2B Customer Orders
18th Oct 20247:00 amRNSResponse to Share Price Movement
27th Sep 20247:00 amRNSMaiden Interim Results
16th Sep 20247:00 amRNSMultiple Placements of Products and B2B Progress
2nd Aug 20243:02 pmRNSNotification of Major Holdings
30th Jul 20247:00 amRNSExercise of Warrants and Total Voting Rights
16th Jul 20247:00 amRNSExercise Warrants PDMR Dealing Total Voting Rights
11th Jul 20247:00 amRNSExercise of Warrants and Total Voting Rights
2nd Jul 20243:31 pmRNSExercise of Warrants and Total Voting Rights
21st Jun 20243:17 pmRNSResult of AGM
17th Jun 202411:22 amRNSExercise Warrants PDMR Dealing Total Voting Rights
11th Jun 20247:00 amRNSExercise Warrants Options and Total Voting Rights
30th May 20247:20 amRNSFinal Year end Results and Notice of AGM
24th May 20244:18 pmRNSExercise of Warrants
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.